NCT07091695 2025-11-12
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
Bristol-Myers Squibb
Completed
Clinical Trials
8 trialsNCT03963518 2025-10-06
SURROGATE-ICI
Institut Bergonié
Completed
NCT02154490 2023-06-01
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Completed
NCT03453892 2023-02-16
ST-ICI
University of Erlangen-Nürnberg Medical School
Completed
NCT03695835 2020-07-22
NIRPA
Gary Onik MD
Completed
NCT03165409 2017-10-05
Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread
Bristol-Myers Squibb
Completed
NCT02739386 2017-04-27
Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases
Bristol-Myers Squibb
Completed
NCT02050594 2015-07-07
Ipilimumab 12-month Intensive Pharmacovigilance Protocol
Bristol-Myers Squibb
Completed